PMID- 36815988
OWN - NLM
STAT- MEDLINE
DCOM- 20230227
LR  - 20230428
IS  - 2167-8359 (Electronic)
IS  - 2167-8359 (Linking)
VI  - 11
DP  - 2023
TI  - Association between human leukocyte antigen (HLA) and end-stage renal disease 
      (ESRD): a meta-analysis.
PG  - e14792
LID - 10.7717/peerj.14792 [doi]
LID - e14792
AB  - OBJECTIVES: We recently studied the association between various human leukocyte 
      antigen (HLA) alleles and end-stage renal disease (ESRD). According to our 
      analysis, HLA-B*50 and HLA-DQA1*3 alleles were positively associated with ESRD, 
      while B*40, DRB1*12, DRB1*13, and DQA1*6 alleles were negatively associated with 
      ESRD. However, a single case-control study does not have enough statistical power 
      to evaluate the possible impact of genetic polymorphism on any disease. Hence, 
      the main objective of this meta-analysis is to determine the association between 
      these abovementioned HLA alleles and ESRD. DESIGN: MEDLINE/PubMed, EMBASE, Web of 
      Science, and Cochrane databases were searched through December 2020 for 
      case-control studies on the associations between HLA polymorphisms and ESRD. 
      Independent reviewers screened the texts of potentially eligible studies and 
      assessed the risk of bias. The meta-analysis was conducted based on the 
      checklists and guidelines based on PRISMA. RESULTS: We identified 26 case-control 
      studies comprising 1,312 ESRD and 3,842 healthy subjects. A non-significant 
      positive association was observed between HLA-B*50 (OR = 1.02, 95% CI [0.90, 
      1.24]), HLA-B*40 (OR = 1.75, 95% CI [0.98, 3.2]), HLA-DQA1*3, (OR = 1.17, 95% CI 
      [0.74, 1.84]), DRB1*12 (OR = 1.05, 95% CI [0.94, 1.18]) alleles and ESRD. In 
      addition, a non-significant negative association was observed between HLA-DRB1*13 
      (OR = 0.90, CI [0.81, 1.01]), HLA-DQB1*6 (OR = 0.79, 95% CI [0.58, 1.07]) alleles 
      and ESRD. CONCLUSIONS: Our meta-analysis indicates no significant association 
      between HLA-B*50, HLA-DQA1*3, B*40, DRB1*12, DRB1*13, and DQA1*6 alleles and 
      ESRD. Further studies with larger sample sizes and adjustments for confounders 
      are required to confirm these conclusions.
CI  - (c)2023 Noureen and Zaidi.
FAU - Noureen, Naila
AU  - Noureen N
AD  - Cancer Biology Lab, Institute of Microbiology and Molecular Genetics, University 
      of the Punjab, Lahore, Pakistan.
AD  - Cancer Research Center (CRC), University of the Punjab, Lahore, Punjab, Pakistan.
FAU - Zaidi, Nousheen
AU  - Zaidi N
AD  - Cancer Biology Lab, Institute of Microbiology and Molecular Genetics, University 
      of the Punjab, Lahore, Pakistan.
AD  - Cancer Research Center (CRC), University of the Punjab, Lahore, Punjab, Pakistan.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20230213
PL  - United States
TA  - PeerJ
JT  - PeerJ
JID - 101603425
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (HLA-B Antigens)
SB  - IM
MH  - Humans
MH  - Case-Control Studies
MH  - Gene Frequency
MH  - Haplotypes
MH  - *Histocompatibility Antigens Class I/genetics
MH  - HLA-B Antigens/genetics
MH  - *Kidney Failure, Chronic/genetics
PMC - PMC9933765
OTO - NOTNLM
OT  - ESRD
OT  - HLA
OT  - HLA polymorphism
OT  - Kidney disease
COIS- The authors declare there are no competing interests.
EDAT- 2023/02/24 06:00
MHDA- 2023/03/03 06:00
PMCR- 2023/02/13
CRDT- 2023/02/23 09:16
PHST- 2022/09/28 00:00 [received]
PHST- 2023/01/03 00:00 [accepted]
PHST- 2023/02/23 09:16 [entrez]
PHST- 2023/02/24 06:00 [pubmed]
PHST- 2023/03/03 06:00 [medline]
PHST- 2023/02/13 00:00 [pmc-release]
AID - 14792 [pii]
AID - 10.7717/peerj.14792 [doi]
PST - epublish
SO  - PeerJ. 2023 Feb 13;11:e14792. doi: 10.7717/peerj.14792. eCollection 2023.